Compass Therapeutics’ Chief Accounting Officer Buys 2,500 Shares Amid 70% Stock Slide and Pending FDA Trial Approval

Insider Buying in a Volatile Market

On September 24, 2026, Compass Therapeutics’ Chief Accounting Officer, Neil Lerner, added 2,500 shares of the company’s common stock to his portfolio at $1.14 per share—an amount that does not alter his overall holdings dramatically but signals a continued belief in the company’s long‑term prospects. The purchase comes at a time when the stock’s price has dropped more than 70 % year‑to‑date, its 52‑week low is just $1.10, and the broader oncology‑biopharma sector remains fraught with regulatory uncertainty. Yet the trade’s timing is noteworthy: it follows a 15,000‑share buy a few months earlier and precedes a potential series of RSU awards that will vest over the next four years. For investors, Lerner’s action may be interpreted as an endorsement of the company’s upcoming regulatory milestones, particularly the FDA’s request for a survival‑benefit trial for tovecimig.

What Investors Should Take Away

The insider transaction aligns with a broader pattern of modest buying by Compass’s executive team. In April, both Lerner and General Counsel Jonathan Anderman each purchased shares, while the CEO, Thomas Schuetz, has been selling—though his sales are largely a result of routine vesting and liquidity needs rather than a signal of distress. The net effect is a relatively stable insider ownership base: the company’s market cap is $210.7 million, and insider holdings remain above 20 % of the shares outstanding. For a clinical‑stage biopharma whose revenue pipeline is still nascent, such stability can be comforting. Nevertheless, the company’s price‑earnings ratio of –2.91 and steep quarterly declines suggest that investors should remain cautious, focusing on upcoming FDA decisions and the company’s ability to raise capital without diluting shareholders.

Lerner Neil: A Profile of Steadiness

Neil Lerner’s insider trading history shows a consistent, low‑profile buying strategy. His most recent purchase in September was preceded by a 15,000‑share buy in April at $1.89 each. Unlike some executives who engage in large, opportunistic trades, Lerner’s transactions are modest and timed near significant corporate events—such as the FDA’s regulatory update in September and the planned submission of the biopharmaceutics license for tovecimig. This pattern suggests a long‑term commitment to Compass’s therapeutic agenda rather than a speculative play on short‑term price movements. It also reflects the role of a Chief Accounting Officer: maintaining confidence in the company’s financial health and governance without triggering market volatility.

Implications for Compass’s Future

With a strong insider support base and a clear focus on regulatory milestones, Compass Therapeutics is positioned to navigate the next phase of its development. The company’s recent clinical data—highlighted by significant improvements in objective response rate and progression‑free survival—provides a solid foundation for the forthcoming survival‑benefit trial. However, the steep drop in share price and negative earnings indicate that investors will need to monitor how effectively Compass can raise additional capital, perhaps through equity or debt, without diluting existing shareholders. As the company continues to progress toward regulatory approval, insider buying—especially by executives like Lerner—may serve as a positive signal that the leadership remains confident in the therapeutic pipeline and the company’s ability to deliver long‑term value.